Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/01—Hydrolysed proteins; Derivatives thereof
  • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
  • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
  • A61K38/015—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen from keratin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/01—Hydrolysed proteins; Derivatives thereof
  • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
  • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/36—Blood coagulation or fibrinolysis factors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/38—Albumins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
  • A61L24/001—Use of materials characterised by their function or physical properties
  • A61L24/0031—Hydrogels or hydrocolloids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
  • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
  • A61L24/043—Mixtures of macromolecular materials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
  • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
  • A61L26/0052—Mixtures of macromolecular compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
  • A61L26/0061—Use of materials characterised by their function or physical properties
  • A61L26/008—Hydrogels or hydrocolloids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2400/00—Materials characterised by their function or physical properties
  • A61L2400/04—Materials for stopping bleeding

Definitions

• the present invention relates to hemostatic compositions and processes for making such compositions.
• Hemostatic compositions in dry storage-stable form that comprise biocompatible, biodegradable, dry stable granular material are known e.g. from WO98/008550A or WO 2003/007845A . These products have been successfully applied in the art for hemostasis.
• Floseal ® is an example for a powerful and versatile hemostatic agent consisting of a granular gelatin matrix swollen in a thrombin-containing solution to form a flowable paste.
• compositions should also be provided in a convenient and usable manner.
• the products should preferably be provided in product formats enabling a convenient provision of "ready-to-use" hemostatic compositions, which can be directly applied to an injury without any time consuming reconstitution steps involved.
• the present invention provides a hemostatic composition comprising:
• compositions according to the present invention improve hemostasis. Furthermore, the compositions according to the present invention show a strong adherence to the tissue when applied to a wound.
• crosslinking reaction Upon contact with bleeding tissue, a crosslinking reaction of the hydrophilic polymeric component with the blood proteins leads to formation of a gel with sealing and hemostatic properties. Crosslinking also occurs to the tissue surface proteins and, depending on the nature of the biocompatible polymer material, may also occur to the biocompatible polymer material. The latter reaction contributes to an improved adhesion of the composition material to the wounded tissue surface.
• a further aspect relates to a hemostatic composition for use in the treatment of an injury.
• kits for the treatment of an injury comprising a hemostatic composition as herein disclosed and instructions for use.
• the present invention also refers to a method for producing the hemostatic composition according to the invention in a convenient manner allowing the composition to be easily at hand for medical use.
• the disclosure further relates to a method for delivering a hemostatic composition to a target site in a patient's body, said method comprising delivering a hemostatic composition produced by the process of the present invention to the target site.
• the present disclosure relates to a finished final container obtained by the process according of the present invention containing the present hemostatic composition.
• the disclosure also relates to a method for providing a ready-to-use hemostatic composition comprising contacting a hemostatic composition produced by the process of the present invention as well as to a kit comprising the finished final container and other means for applying the composition.
• the compositions according to the present invention are particularly useful for providing hemostasis at bleeding sites, including surgical bleeding sites, traumatic bleeding sites and the like.
• An exemplary use of the compositions may be in sealing the tissue tract above a blood vessel penetration created for vascular catheterization.
• the present invention provides an improvement in hemostatic compositions.
• the hemostatic compositions according to the present invention contain biocompatible polymers in particulate form, e.g. granules of a crosslinked gelatin suitable for use in hemostasis (the "hemostatic biocompatible polymer component” or the “hemostatic polymer”).
• Admixed to this biocompatible polymer for hemostasis is one hydrophilic polymeric component comprising electrophilic reactive groups.
• the reactive groups of the polymeric component have retained their reactivity until the composition is brought to the place of clinical action, e.g. onto the wound.
• the biocompatible polymers in particulate form suitable for use in hemostasis may include dimensionally isotropic or non-isotropic forms.
• the biocompatible polymers according to the present invention may be granules or fibers; and may be present in discontinuous structures, for example in powder forms.
• the biocompatible polymer is liquid absorbing.
• the polymer upon contact with liquids, e.g. aqueous solutions or suspensions (especially a buffer or blood) the polymer takes up the liquid and will display a degree of swelling, depending on the extent of hydration.
• the material preferably absorbs from about 200% to about 2000%, especially from about 400% to about 1300% water or aqueous buffer by weight, corresponding to a nominal increase in diameter or width of an individual particle of subunit in the range from e.g. approximately 50% to approximately 500%, usually from approximately 50% to approximately 250%.
• the fully hydrated composition e.g. after administration on a wound or after contact with an aqueous buffer solution
• the fully hydrated composition may have a size range of 0.05 mm to 3 mm, especially of 0.25 mm to 1.5 mm.
• the equilibrium swell of preferred biocompatible polymers of the present invention may generally range e.g. from 400% to 1300%, preferably being from 500% to 1100%, depending on its intended use.
• Such equilibrium swell may be controlled e.g. (for a crosslinked polymer) by varying the degree of crosslinking, which in turn is achieved by varying the crosslinking conditions, such as the type of crosslinking method, duration of exposure of a crosslinking agent, concentration of a crosslinking agent, crosslinking temperature, and the like.
• Materials having differing equilibrium swell values perform differently in different applications. For example, the ability to inhibit bleeding in a liver divot model was most readily achieved with crosslinked gelatin materials having a swell in the range from 700% to 950%.
• the biocompatible polymer in particulate form suitable for use in hemostasis and the hydrophilic polymeric component are present in a solid matrix.
• Biocompatible polymers in particulate form suitable for use in hemostasis may be formed from biologic and non-biologic polymers.
• Suitable biologic polymers may contain a protein, a polysaccharide, a biologic polymer, a non-biologic polymer; and derivatives and combinations thereof.
• Suitable proteins include gelatin, collagen, albumin, hemoglobin, fibrinogen, fibrin, casein, fibronectin, elastin, keratin, and laminin; and derivatives and combinations thereof.
• Particularly preferred is the use of gelatin or soluble non-fibrillar collagen, more preferably gelatin, and exemplary gelatin formulations are set forth below.
• Suitable biologic polymers include polysaccharides, such as glycosaminoglycans, starch, cellulose, dextran, hemicellulose, xylan, agarose, alginate and chitosan; and derivatives and combinations thereof.
• Suitable non-biologic polymers will be selected to be degradable by either of two mechanisms, i.e. (1) break down of the polymeric backbone or (2) degradation of side chains which result in aqueous solubility.
• non-biologic biocompatible polymers suitable for use in hemostasis include synthetics, such as polyacrylates, polymethacrylates, polyacrylamides, polymethacrylamides, polyethyleneimines, polyvinyl resins, polylactide-glycolides, polycaprolactones, and polyoxyethlenes; and derivatives and combinations thereof. Also combinations of different kinds of polymers are possible (e.g. proteins with polysaccharides, proteins with non-biologic hydrogel-forming polymers, etc.).
• Preferred hemostatic polymers comprise amino-groups, specifically if the hydrophilic polymeric component has reactive groups which react with amino-groups upon administration (e.g. in the wound environment).
• a derivative thereof includes any chemically modified polymer, such as e.g. a crosslinked polymer.
• Preferred hemostatic polymers comprise nucleophilic groups, such as e.g. amino-groups, specifically if the hydrophilic polymeric component has reactive groups which react with amino-groups upon administration (e.g. in the wound environment).
• the biocompatible polymer is crosslinked gelatin.
• a non-crosslinked polymer may be crosslinked in any manner suitable to reconstitute, e.g. to form a suitable hydrogel base of the hemostatic polymer.
• polymeric molecules may be crosslinked using bi- or poly-functional crosslinking agents which covalently attach to two or more polymer molecules chains.
• bifunctional crosslinking agents include aldehydes, epoxides, succinimides, carbodiimides, maleimides, azides, carbonates, isocyanates, divinyl sulfone, alcohols, amines, imidates, anhydrides, halides, silanes, diazoacetate, aziridines, and the like.
• crosslinking may be achieved by using oxidizers and other agents, such as periodates, which activate side-chains or moieties on the polymer so that they may react with other side-chains or moieties to form the crosslinking bonds.
• An additional method of crosslinking comprises exposing the polymers to radiation, such as gamma radiation, to activate the polymer chains to permit crosslinking reactions.
• Dehydrothermal crosslinking methods may also be suitable. Preferred methods for crosslinking gelatin molecules are described below.
• the biocompatible hemostatic polymer - once applied to a wound - forms an efficient matrix which can form a barrier for blood flow.
• the swelling properties of the hemostatic polymer can make it an effective mechanical barrier against bleeding and re-bleeding processes.
• the hemostatic compositions according to the present invention are provided or used as granular preparations.
• the biocompatible polymer suitable for use in hemostasis is in particulate form, preferably a granular material.
• This granular material can rapidly swell when exposed to a fluid (i.e. the diluent) and in this swollen form is capable of contributing to a flowable paste that can be applied to a bleeding site.
• the biocompatible polymer i.e. crosslinked gelatin, may be provided as a film which can then be milled to form a granular material.
• Most of the particles contained in this granular material e.g. more than 90% w/w
• the biocompatible polymer in particulate form suitable for use in hemostasis is a crosslinked gelatin.
• Dry crosslinked gelatin powder can be prepared to re-hydrate rapidly if contacted with a pharmaceutically acceptable diluent.
• the gelatin granules, especially in the form of a gelatin powder preferably comprise relatively large particles, also referred to as fragments or sub-units, as described in WO98/08550A and WO2003/007845A .
• the (median) particle size will be the range from 10 to 1000 ⁇ m, preferably from 50 to 700 ⁇ m.
• the swell will be in the range from 400% to 1000%.
• "Equilibrium swell” may be determined by subtracting the dry weight of the gelatin hydrogel powder from its weight when fully hydrated and thus fully swelled. The difference is then divided by the dry weight and multiplied by 100 to give the measure of swelling.
• the dry weight should be measured after exposure of the material to an elevated temperature for a time sufficient to remove substantially all residual moisture, e.g., two hours at 120°C.
• the equilibrium hydration of the material can be achieved by immersing the dry material in a pharmaceutically acceptable diluent, such as aqueous saline, for a time period sufficient for the water content to become constant, typically for from 18 to 24 hours at room temperature.
• a pharmaceutically acceptable diluent such as aqueous saline
• the pharmaceutically acceptable diluent further comprises thrombin, preferably 10 to 1000 I.U. thrombin/ml, especially 250 to 700 I.U. thrombin/ml.
• the hemostatic composition in this ready to use form contains 10 to 100.000 International Units (I.U.) of thrombin, more preferred 100 to 10.000 I.U., especially 500 to 5.000 I.U..
• the thrombin concentration in the ready-to-use composition is preferably in the range of 10 to 10.000 I.U., more preferred of 50 to 5.000 I.U., especially of 100 to 1.000 I.U./ml.
• the diluent is used in an amount to achieve the desired end-concentration in the ready-to-use composition.
• the thrombin preparation may contain other useful component, such as ions, buffers, excipients, stabilizers, etc..
• Thrombin (or any other coagulation inducing agent, such as a snake venom, a platelet activator, a thrombin receptor activating peptide and a fibrinogen precipitating agent) can be derived from any thrombin preparation which is suitable for use in humans (i.e. pharmaceutically acceptable).
• Suitable sources of thrombin include human or bovine blood, plasma or serum (thrombin of other animal sources can be applied if no adverse immune reactions are expected) and thrombin of recombinant origin (e.g. human recombinant thrombin); autologous human thrombin can be preferred for some applications.
• Exemplary methods for producing crosslinked gelatins are as follows. Gelatin is obtained and suspended in an aqueous solution to form a non-crosslinked hydrogel, typically having a solids content from 1% to 70% by weight, usually from 3% to 10% by weight. The gelatin is crosslinked, typically by exposure to either glutaraldehyde (e.g., 0.01% to 0.05% w/w, overnight at 0°C. to 15°C in aqueous buffer), sodium periodate (e.g., 0.05 M, held at 0°C. to 15°C.
• glutaraldehyde e.g., 0.01% to 0.05% w/w, overnight at 0°C. to 15°C in aqueous buffer
• sodium periodate e.g., 0.05 M, held at 0°C. to 15°C.
• gelatin particles can be suspended in an alcohol, preferably methyl alcohol or ethyl alcohol, at a solids content of 1% to 70% by weight, usually 3% to 10% by weight, and crosslinked by exposure to a crosslinking agent, typically glutaraldehyde (e.g., 0.01% to 0.1% w/w, overnight at room temperature).
• a crosslinking agent typically glutaraldehyde (e.g., 0.01% to 0.1% w/w, overnight at room temperature).
• the pH should be held from about 6 to 11, preferably from 7 to 10.
• the crosslinks are formed via Schiff bases which may be stabilized by subsequent reduction, e.g., by treatment with sodium borohydride.
• the resulting granules may be washed in water and optionally rinsed in an alcohol, and dried. The resulting dry powders may then be provided in the final container as described herein.
• the biocompatible polymer is provided in a dry granular form for producing the hemostatic compositions according to the present invention.
• a "dry granular preparation of a biocompatible polymer" according to the present invention is known e.g. from WO 98/08550 A .
• the polymer is a biocompatible, biodegradable dry stable granular material.
• the dry polymer according to the present invention is provided with particle sizes of 10 to 1000 ⁇ m.
• the polymer particles have a mean particle diameter ("mean particle diameter” is the median size as measured by laser diffractometry; "median size” (or mass median particle diameter) is the particle diameter that divides the frequency distribution in half; fifty percent of the particles of a given preparation have a larger diameter, and fifty percent of the particles have a smaller diameter) from 10 to 1000 ⁇ m, especially 50 to 700 ⁇ m (median size).
• mean particle diameter is the median size as measured by laser diffractometry
• median size mass median particle diameter
• Applying larger particles is mainly dependent on the medical necessities; particles with smaller mean particle diameters are often more difficult to handle in the production process.
• the dry polymer is therefore provided in granular form.
• powders are defined herein as a special sub-class of granular materials.
• powders refer to those granular materials that have the finer grain sizes, and that therefore have a greater tendency to form clumps when flowing.
• Granules include coarser granular materials that do not tend to form clumps except when wet.
• the particles used are those which can be coated by suitable coating techniques Particle size of the polymer granules according to the present invention can therefore easily be adapted and optimized to a certain coating technique by the necessities of this technique.
• the hydrophilic polymeric component (also referred to as "reactive hydrophilic component” or “hydrophilic (polymeric) crosslinker”) of the hemostatic composition according to the present invention is a hydrophilic crosslinker which is able to react with its reactive groups once the hemostatic composition is applied to a patient (e.g. to a wound of a patient or another place where the patient is in need of a hemostatic activity). Therefore it is important for the present invention that the reactive groups of the polymeric component are reactive when applied to the patient. It is therefore necessary to manufacture the hemostatic composition according to the present invention so that the reactive groups of the polymeric component which should react once they are applied to a wound are retained during the manufacturing process.
• hydrophilic polymeric components have reactive groups which are susceptible to hydrolysis after contact with water. Accordingly, premature contact with water or aqueous liquids has to be prevented before administration of the hemostatic composition to the patient, especially during manufacture.
• processing of the hydrophilic polymeric component during manufacturing may be possible also in an aqueous medium at conditions where the reactions of the reactive groups are inhibited (e.g. at a low pH). If the hydrophilic polymeric components can be melted, the melted hydrophilic polymeric components can be sprayed or printed onto the matrix of the biopolymer. It is also possible to mix a dry form (e.g.
• hydrophilic polymeric component a powder of the hydrophilic polymeric component with a dry form of the biocompatible polymer suitable for use in hemostasis. If necessary, then an increase of the temperature can be applied to melt the sprinkled hydrophilic polymeric component to the biocompatible polymer suitable for use in hemostasis to achieve a permanent coating of the hemostatic composition.
• these hydrophilic polymeric components can be taken up into inert organic solvents (inert vis-à-vis the reactive groups of the hydrophilic polymeric components) and brought onto the matrix of the biomaterial. Examples of such organic solvents are dry ethanol, dry acetone or dry dichloromethane (which are e.g. inert for hydrophilic polymeric components, such as NHS-ester substituted PEGs).
• one hydrophilic polymeric component comprising reactive groups means that the presence of a second or further hydrophilic polymeric component with nucleophilic reactive groups is excluded in a hemostatic composition according to the present invention.
• the hydrophilic polymer component is a single hydrophilic polymer component and is a polyalkylene oxide polymer, preferably a PEG comprising polymer.
• the reactive groups of this reactive polymer are electrophilic groups.
• the reactive hydrophilic component may be a multi-electrophilic polyalkylene oxide polymer, e.g. a multi-electrophilic PEG.
• Preferred electrophilic groups of the hydrophilic polymeric crosslinker according to the present invention are groups reactive to the amino-, carboxy-, thiol- and hydroxy- groups of proteins, or mixtures thereof.
• Preferred carboxy-group specific reactive groups are amino-groups in the presence of carbodiimides.
• Preferred thiol group-specific reactive groups are maleimides or haloacetyls.
• Preferred hydroxy group-specific reactive group is the isocyanate group.
• the reactive groups on the hydrophilic crosslinker may be identical (homofunctional) or different (heterofunctional).
• the hydrophilic polymeric component can have two reactive groups (homobifunctional or heterobifunctional) or more (homo/hetero-trifunctional or more).
• the material is a synthetic polymer, preferably comprising PEG.
• the polymer can be a derivative of PEG comprising active side groups suitable for crosslinking and adherence to a tissue.
• the hydrophilic reactive polymer has the ability to crosslink blood proteins and also tissue surface proteins. Crosslinking to the biomaterial is also possible.
• the multi-electrophilic polyalkylene oxide may include two or more succinimidyl groups.
• the multi-electrophilic polyalkylene oxide may include two or more maleimidyl groups.
• the multi-electrophilic polyalkylene oxide is a polyethylene glycol or a derivative thereof.
• the hydrophilic polymeric component is a hydrophilic crosslinker.
• this crosslinker has more than two reactive groups for crosslinking ("arms"), for example three, four, five, six, seven, eight, or more arms with reactive groups for crosslinking.
• arms for example, NHS-PEG-NHS is an effective hydrophilic crosslinker according to the present invention.
• a 4-arm polymer e.g. 4-arms-p-NP-PEG
• an 8-arm polymer e.g. 8-arms-NHS-PEG may even be more preferred for those embodiments where multi-reactive crosslinking is beneficial.
• the hydrophilic crosslinker according to the present invention is a polymer, i.e. a large molecule (macromolecule) composed of repeating structural units which are typically connected by covalent chemical bonds.
• the hydrophilic polymer component according to the present invention should have a molecular weight of at least 1000 Da (to properly serve as crosslinker in the hemostatic composition according to the present invention); preferably the crosslinking polymers according to the present invention has a molecular weight of at least 5000 Da, especially of at least 8000 Da.
• hydrophilic crosslinkers For some hydrophilic crosslinkers, the presence of basic reaction conditions (e.g. at the administration site) is preferred or necessary for functional performance (e.g. for a faster crosslinking reaction at the administration site).
• carbonate or bicarbonate ions e.g. as a buffer with a pH of 7.6 or above, preferably of 8.0 or above, especially of 8.3 and above
• may be additionally provided at the site of administration e.g. as a buffer solution or as a fabric or pad soaked with such a buffer), so as to allow an improved performance of the hemostatic composition according to the present invention or to allow efficient use as a hemostatic and/or wound adherent material.
• the reactivity of the hydrophilic polymeric component (which, as mentioned, acts as a crosslinker) in the composition according to the present invention is retained in the composition.
• this includes the omitting of aqueous conditions (or wetting), especially wetting without the presence of acidic conditions (if crosslinkers are not reactive under acidic conditions). This allows the provision of reactive hemostatic materials.
• the biocompatible polymer is crosslinked gelatin and the hydrophilic polymeric component is pentaerythritolpoly(ethyleneglycol)ether tetrasuccinimidyl glutarate.
• Preferred ratios of the biocompatible polymer to hydrophilic polymeric component in the hemostatic composition according to the present invention are from 0.1 to 50 % w/w, preferably from 5 to 40 %w/w.
• the present hemostatic composition is provided in a solid matrix, and the use of collagen in (or as) the solid matrix is specifically preferred.
• An advantage of the hemostatic composition being provided in solid form is that such solid forms may be separable by mechanical means. This allows specific dimensioning of the hemostatic composition at the place of use, e.g. during surgery immediately before or during administration.
• the "solid matrix” according to the present invention forms - together with the biocompatible polymer and the hydrophilic polymeric component - a solid form of the composition according to the present invention which may retain its 3-dimensional form in a robust manner. Accordingly, the solid matrix also acts as a "matrix forming component" for the hemostatic ingredients of the composition according to the present invention.
• Preferred solid matrices according to the present invention provide a porous structure and/or a fibrous network which allows liquids (e.g. blood, a buffer or reactive components) to enter the matrix.
• These matrices according to the present invention include woven and nonwoven materials. They may show a continuous phase or be present in discontinuous phases (e.g. multi-layered).
• the solid matrix according to the present invention is a permeable matrix. It may be provided as a temporary (e.g. biodegradable or permanent matrix.
• the solid matrix comprises nucelophilic groups, such as amino groups.
• the present hemostatic composition is preferably provided in lyophilized form.
• transport and storage properties are significantly improved which enables the use of the present invention also in places where steady cooling cannot be guaranteed.
• the hemostatic compositions according to the present invention may further comprise a substance selected from the group consisting of antifibrinolytic, procoagulant, platelet activator, antibiotic, vasoconstrictor, dye, growth factors, bone morphogenetic proteins and pain killers.
• the present invention relates to a hemostatic composition according to the present invention for use in the treatment of an injury selected from the group consisting of a wound, a hemorrhage, damaged tissue, bleeding tissue and/or bone defect.
• the present invention provides a kit for the treatment of an injury selected from the group consisting of a wound, a hemorrhage, damaged tissue and/or bleeding tissue comprising
• the present invention also relates to a method for producing a hemostatic composition according to the present invention comprising the step of mixing, preferably blending, a biocompatible polymer suitable for use in hemostasis and one hydrophilic polymeric component comprising reactive groups with a matrix-forming component under conditions wherein the reactivity of the polymeric component is retained and drying said composition, preferably by freeze-drying, wherein the biocompatible polymer is a crosslinked gelatin and wherein the hydrophilic polymeric component is a hydrophilic crosslinker with electrophilic reactive groups.
• the present disclosure also provides a method for delivering a hemostatic composition according to the invention to a target site in a patient's body, said method comprising delivering a hemostatic composition produced by the process according to the present invention to the target site.
• this method for delivering is not part of the present invention.
• the dry composition can be directly applied to the target site (and, optionally be contacted with the pharmaceutically acceptable diluent a the target site, if necessary), it is preferred to contact the dry hemostatic composition with a pharmaceutically acceptable diluent before administration to the target site, so as to obtain a hemostatic composition in a wetted form, especially a hydrogel form.
• the present disclosure also refers to a finished final container obtained by the process according to the present invention.
• This finished container contains the combined components in a sterile, storage-stable and marketable form.
• the final container can be any container suitable for housing (and storing) pharmaceutically administrable compounds.
• the collagen concentration of the material obtained was determined by gravimetry.
• a chemical crosslinking with glutaraldehyde may be carried out in that a 1% aq. collagen suspension was prepared and 5000ppm of glutaraldehyde are added at 12°C. A suspension obtained was stirred overnight. Crosslinked collagen obtained was filtered and washed with H 2 O. The collagen concentration of the material obtained was determined by gravimetry as described above.
• Example 2 Preparation of a hemostatic, NHS-PEG impregnated solid form of crosslinked gelatin particles embedded in a loose collagen network.
• heparinized pig 1.5 x ACT
• a liver lobe was punctured by stabbing with a tool containing two perpendicular sharp blades (2 cm width each).
• a cross-shaped perforation of the liver lobe was obtained.
• the pouch containing the hemostatic solid form according to Example 2 was opened and the necessary amount of material was broken from the preparation.
• the material was stuffed with the aid of surgical gloves into the bleeding wound.
• the wound containing the hemostatic material was compressed for 3 minutes from both ends of the perforation using surgical gloves. The strong bleeding was stopped by this treatment.

Priority Applications (1)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=47022655

Family Applications (2)

Family Applications After (1)

Country Status (11)

Families Citing this family (24)

Family Cites Families (19)

• 2012
  • 2012-10-10 AU AU2012318256A patent/AU2012318256B2/en active Active
  • 2012-10-10 WO PCT/EP2012/070054 patent/WO2013053753A2/en active Application Filing
  • 2012-10-10 JP JP2014535045A patent/JP6195567B2/ja active Active
  • 2012-10-10 EP EP12772918.4A patent/EP2766060B1/en active Active
  • 2012-10-10 MX MX2014004476A patent/MX355924B/es active IP Right Grant
  • 2012-10-10 CA CA2851332A patent/CA2851332C/en active Active
  • 2012-10-10 ES ES12772918T patent/ES2938541T3/es active Active
  • 2012-10-10 US US13/648,789 patent/US20130096062A1/en not_active Abandoned
  • 2012-10-10 EP EP22200796.5A patent/EP4137166A1/en active Pending
  • 2012-10-10 CN CN201280057486.1A patent/CN103998068B/zh active Active
  • 2012-10-10 KR KR1020147012291A patent/KR102143252B1/ko active IP Right Grant
• 2014
  • 2014-04-06 IL IL231962A patent/IL231962A0/en unknown
• 2017
  • 2017-04-26 JP JP2017087065A patent/JP2017153975A/ja active Pending

Also Published As

Similar Documents

Legal Events